守护肠道健康标志(导航栏右侧图标)守护肠道健康

REVIEWS & SCIENCE

综述与科普

综述转载 2026-11-04

产丁酸菌对化疗增效减毒机制的研究进展

王凯、王蒙、刘子愫 · 丁香园

本文为转载内容,版权归原作者及原发布平台所有;若涉及版权问题请联系我们删除。原文链接

王凯¹、王蒙²、刘子愫³

¹ 陕西省第二人民医院;² 陕西中医药大学 2024 级研究生;³ 陕西中医药大学 2025 级研究生

【摘要】化疗是当前肿瘤综合治疗的重要支柱手段,广泛应用于多种恶性肿瘤的新辅助治疗、术后辅助治疗及晚期姑息治疗中。然而,临床上约20%~50%的肿瘤患者对初始化疗方案不敏感,即使初始有效的患者最终也大多因获得性耐药而出现疾病进展。不仅如此,化疗所致的严重毒副反应常导致治疗减量或中断,疗效与毒副反应的双重困境始终是临床面临的重大挑战。产丁酸菌作为肠道基石菌,通过分泌代谢产物丁酸发挥“增效减毒”的双重作用。其中,酪酸梭菌作为研究最深入、应用最广泛的代表性产丁酸菌之一,其制剂已投入临床应用。本文系统综述产丁酸菌对化疗增效减毒机制的研究进展,为基于微生态干预的肿瘤化疗优化策略提供理论依据。

【关键词】产丁酸菌;丁酸;增效;酪酸梭菌;基石菌;毒副作用

1 引言

恶性肿瘤(癌症)是严重威胁人类生命健康的重大疾病。2022年全球新发恶性肿瘤约2000万例、死亡人数约970万[1];其中,我国新发恶性肿瘤约482.47万例、死亡约257.42万例,分别约占全球新发和死亡病例的24.2%和26.4%[1-3]。目前,肿瘤治疗手段主要包括手术切除、放射治疗、化学治疗及近年来快速发展的免疫疗法,其中化学治疗凭借广谱的细胞杀伤效应和广泛的适应症,在肿瘤综合治疗体系中占据重要地位[4, 5],贯穿术前新辅助、术后辅助及晚期姑息治疗等多个阶段[6]。临床常用化疗药物包括铂类化合物(如顺铂、奥沙利铂)、氟尿嘧啶类抗代谢药及蒽环类抗生素等,主要通过干扰DNA合成与复制、诱导DNA损伤发挥抗肿瘤效应[5]。

然而,化疗的临床应用面临两大核心瓶颈。其一,化疗耐药。根据耐药发生的时间和机制,将其分为原发性耐药与获得性耐药:原发性耐药是指肿瘤在治疗开始前即对化疗药物不敏感,导致患者难以从初始治疗中获益;获得性耐药则是指肿瘤在初始治疗有效后,于持续药物暴露及克隆选择等过程中逐渐产生耐药性,最终引起疾病进展或复发[5, 7]。如5-氟尿嘧啶(5-FU)是结直肠癌姑息治疗和辅助化疗的核心药物之一,但其临床疗效常因肿瘤原发或获得性耐药而受限[6]。其二,化疗药物的毒副作用。化疗药物缺乏肿瘤选择性,在杀伤肿瘤细胞的同时,对消化道黏膜上皮等正常组织造成损伤,诱发肠道黏膜炎、腹泻、恶心、呕吐等不良反应[8, 9]。据统计,约40%接受标准剂量化疗的患者会发生胃肠道毒性,而在接受高剂量化疗的患者中,该比例可达60%-100%[10]。此外,一项纳入447例胃肠癌化疗患者的研究显示,73.4%的患者出现化疗相关黏膜炎症状,其中腹泻、恶心和呕吐的发生率分别为41.6%、37.8%和25.1%,3.1%的患者因无法耐受相关毒性而中止治疗[8, 9]。因此,寻找既能让化疗“增效”(使不敏感的变敏感、使已耐药的复敏),又能“减毒”(保护正常组织、保障疗程完成)的策略,是肿瘤治疗领域亟待解决的重要临床问题。

近年来,随着肠道微生物组学的兴起,越来越多的临床研究表明,产丁酸菌的丰度与多种肿瘤的化疗应答率呈显著正相关[11-13]。在一项局部晚期直肠癌新辅助放化疗患者中,化疗应答者的基线肠道菌群以产丁酸菌显著富集为特征,而不应答者产丁酸菌显著降低[12]。另一项纳入130例食管癌、胃癌及结直肠癌患者的前瞻性队列同样发现,产丁酸菌在化疗有效者体内丰度上升,而在无效者体内显著下降,并推测产丁酸菌是化疗疗效的预测因子[13]。2024年Wu等[14]提出的肠道核心菌群“跷跷板模型”明确指出,产丁酸菌是维系肠道微生态平衡的关键功能类群。作为肠道基石菌,产丁酸菌为肠上皮细胞提供能量、并维持肠黏膜屏障完整与免疫稳态[14]。越来越多研究表明,产丁酸菌发挥着“增效减毒”的作用:一方面,产丁酸菌及其代谢产物丁酸能通过表观遗传调控[15, 16]、逆转耐药[17]、诱导免疫原性细胞死亡[18]等多重机制增强肿瘤对化疗的敏感性;另一方面,其修复肠黏膜屏障、抑制系统性炎症等作用能减轻化疗所致的黏膜炎、腹泻等毒副作用,发挥出“增效减毒”的双重作用[19]。

2 产丁酸菌匮乏造成化疗不敏感的病理机制

临床队列研究证实,产丁酸菌的基线丰度与化疗客观缓解率呈显著正相关,低丰度患者无进展生存期显著缩短[11, 18]。产丁酸菌匮乏通过多条相互交织的病理通路加重化疗耐药和毒副作用。具体而言:(1)表观遗传调控异常与化疗敏感性下降。丁酸是经典的组蛋白去乙酰化酶(HDAC)抑制剂,其生理功能的核心在于维持组蛋白的乙酰化水平[20]。当产丁酸菌匮乏,丁酸不足时,HDAC活性失去抑制,组蛋白H3/H4乙酰化水平随之下降,抑癌基因(如p21、p27及促凋亡基因)的转录受到抑制。这一表观遗传层面的改变,削弱了肿瘤细胞对化疗药物诱导凋亡的敏感性[15, 16, 20];不仅如此,丁酸不足会上调药物外排泵(如ABC转运蛋白)和DNA修复基因表达,增强药物外排与损伤修复能力,从而驱动获得性耐药[15, 16, 18]。此外,产丁酸菌匮乏,MYC等致癌蛋白稳定性增加,TYMS表达上调,导致5-FU等化疗药物的靶点被竞争性抑制,从而直接削弱了化疗敏感性[17]。(2)免疫微环境监视失守。丁酸通过IL-12信号通路,促进CD8⁺ T细胞产生IFN-γ与颗粒酶B等细胞毒性效应分子[21];同时,丁酸通过上调转录调节因子ID2,增强CD8⁺ T细胞的抗肿瘤活性与肿瘤内浸润密度[22]。产丁酸菌匮乏会导致丁酸不足,削弱了T细胞在肿瘤组织的浸润与功能,使得化疗诱导的肿瘤细胞死亡无法被免疫系统有效清除[18, 23]。这种免疫抑制状态不仅降低了化疗疗效,还阻碍了免疫联合治疗的响应[18, 23]。(3)肠道屏障与减毒保护失守。丁酸是结肠上皮细胞的主要能量来源[24]。产丁酸菌匮乏导致丁酸不足,紧密连接蛋白表达下调,肠道屏障完整性受损[25]。在化疗期间,脆弱的肠道屏障无法抵御药物毒性,极易诱发严重的黏膜炎、腹泻等毒副作用,迫使临床降低化疗剂量或中断治疗[9]。(4)化疗药物本身会直接损伤肠屏障和肠道菌群失调,诱发化疗后黏膜损伤、腹泻等毒副作用[26];其次,化疗药物会直接杀伤产丁酸菌,降低肠道产丁酸菌的丰度,进一步加重和放大上述危害,加重化疗不敏感和毒副作用[27]。综上,产丁酸菌匮乏通过“增耐药、弱免疫、损屏障”三条路径,共同导致化疗不敏感性及毒副作用加重。而补充产丁酸菌、恢复产丁酸菌丰度是逆转这一病理现象的关键策略。

3 产丁酸菌在化疗中增效减毒的相关作用机制

3.1 HDAC抑制与表观遗传重编程

丁酸作为经典HDAC抑制剂,增加组蛋白H3等位点乙酰化水平,开放染色质,激活沉默的抑癌/促凋亡基因;显著上调BAX、BAK、CASP3和p21,下调BCL-2和BCL-xL促进凋亡;可逆转异常甲基化或组蛋白修饰导致的耐药;协同依托泊苷放大DNA损伤信号。丁酸对HDAC的抑制具细胞类型特异性——正常结肠上皮细胞中作为能量来源激活HAT1促生长,肿瘤细胞中发挥HDAC抑制诱导凋亡,使其成为理想化疗增敏剂。

3.2 增强肿瘤细胞凋亡

丁酸直接增强肿瘤细胞凋亡敏感性:激活线粒体凋亡通路,促进Bax/Bcl-2失衡、细胞色素C释放、激活caspase级联;促使Ku70-Bax抑制复合物解离释放游离Bax,增强依托泊苷等DNA损伤剂的毒性;通过下调抗凋亡miRNA(如miR-7641、miR-199)解除凋亡通路抑制,协同化疗增强杀伤。

3.3 调节免疫原性细胞死亡(ICD)

丁酸是一种ICD增强剂,通过IRF2-Oasl2-cGAS通路增强ICD,促进树突状细胞成熟与细胞毒性CD8⁺ T细胞招募;上调ID2并增强IL-12信号通路,促进CD8⁺ T细胞增殖、IFN-γ产生及细胞毒性功能。在结直肠癌中,丁酸可放大奥沙利铂诱导的ICD效应,使化疗诱导的细胞死亡转化为抗肿瘤免疫应答。

3.4 调控铁死亡

丁酸通过激活FFAR2受体调控PPAR-γ/PINK1/Parkin信号通路抑制线粒体自噬,使受损线粒体累积,促进ROS生成和脂质过氧化,放大铁死亡信号;在PDAC和肺癌模型中降低GPX4表达、增强脂质过氧化促进铁死亡,使对凋亡通路抵抗的肿瘤对铁死亡敏感。

3.5 逆转耐药

丁酸下调P-糖蛋白(P-gp/ABCB1)、MRP1和GST-π,减少药物外排、恢复胞内药物浓度;在Caco-2细胞中抑制P-gp和MRP功能,改善对顺铂的反应;酪酸梭菌处理增强MYC泛素化,抑制c-MYC表达、下调TYMS,恢复5-FU敏感性;丁酸还可通过杀伤具核梭杆菌逆转该致病菌诱导的化疗耐药。

3.6 减轻化疗副作用

丁酸作为结肠上皮主要能量底物,促进紧密连接蛋白(Claudin-3、Occludin、ZO-1)表达,增强屏障完整性、降低通透性;通过GPR43/GPR109A抑制NF-κB,减少IL-1β、IL-6、TNF-α,增加IL-10;一项纳入41例含铂化疗肺癌患者的RCT显示,连续3周补充酪酸梭菌后化疗相关性腹泻发生率显著低于安慰剂组;丁酸抑制伊立替康诱导的β-葡萄糖醛酸酶活性升高,阻断迟发性腹泻;酪酸梭菌联合用药抑制5-羟色胺、速激肽1及其受体表达,改善恶心呕吐。

4 产丁酸菌在不同肿瘤化疗中的应用研究

4.1 结直肠癌

产丁酸菌缺失与化疗耐药显著相关,丰度与疗效正相关。王沁等92例FOLFOX4化疗患者RCT:联合酪酸梭菌活菌片8周后,肿瘤标志物(CA724、CA199、CEA)降低,免疫功能提升,炎症因子下降,肠黏膜屏障(D-乳酸、sIgA)改善,毒副反应显著降低;另一项60例直肠癌新辅助放化疗研究亦证实其减轻不良反应。5-FU耐药小鼠模型中口服酪酸梭菌显著抑制耐药肿瘤生长,机制为破坏MYC稳定性、抑制TYMS表达;丁酸通过ID2依赖的IL-12信号通路增强CD8⁺ T细胞应答,提高化疗及免疫治疗敏感性。

4.2 肺癌

酪酸梭菌通过维护黏膜屏障、恢复菌群平衡、抑制系统性炎症减轻毒性并提高敏感性。41例铂类联合化疗患者口服3周后,无腹泻比例从38.09%升至75%,恶心呕吐减轻,NLR、PLR下降、LMR升高;一项RCT显示补充酪酸梭菌改善NS-NSCLC患者客观缓解率与无进展生存期;Tomita等106例晚期NSCLC患者中,补充后便秘缓解率62%,非特异性腹部症状缓解率20%,并展现显著生存获益。

4.3 胃癌

130例消化道肿瘤化疗队列显示应答者产丁酸菌富集、不应答者下降;新辅助化疗胃癌患者围手术期补充可减轻腹泻、恶心及黏膜炎;酪酸梭菌对多种化疗药物所致菌群紊乱和腹泻疗效良好。

4.4 胰腺癌

产丁酸菌丰度下降与化疗不敏感及不良预后相关。Yang等证实酪酸梭菌及丁酸促进PDAC铁死亡敏感性,提出丁酸联合RSL3新策略;Han等发现口服酪酸梭菌通过肠-胰轴增强化疗效果且无明显毒副作用。

5 酪酸梭菌的临床价值与应用前景

产丁酸菌(尤其酪酸梭菌)通过“增效”与“减毒”双重机制解决化疗两大临床困境。其价值不局限于化疗:在免疫治疗中,通过增强树突状细胞抗原提呈、促进效应T细胞浸润,提高PD-1/PD-L1抑制剂应答率,助力“冷”肿瘤转“热”;在放疗中,减轻胃肠道不良反应与炎性反应、减小对营养状况的影响。

在国家863项目支持下,医用微生态制品开发国家地方联合工程研究中心筛选出高活性酪酸梭菌菌株CGMCC0313-1,在高密度发酵、微囊化制剂工艺上取得突破并实现产业化。酪酸梭菌被国家药品监督管理局批准为绿标OTC国药准字药品(S20040084,S20040088)。在免疫治疗、放化疗启动前及疗程中常规联用酪酸梭菌制剂以增效减毒,具有重要临床价值与应用前景。

6 总结

产丁酸菌丰度与多种肿瘤化疗应答率密切相关——化疗会降低产丁酸菌丰度,而匮乏又通过肠屏障损伤、系统炎症、免疫抑制等机制进一步降低化疗敏感性,形成恶性循环。补充产丁酸菌通过六大机制增效减毒:(1)HDAC抑制介导的表观遗传重编程恢复抑癌基因表达;(2)上调促凋亡蛋白/下调抗凋亡蛋白增强凋亡;(3)提升化疗诱导的免疫原性;(4)调控GPX4等诱导铁死亡;(5)逆转耐药;(6)修复肠屏障、抑制炎症减轻毒副作用。上述机制在结直肠癌、肺癌、胃癌等得到验证,以结直肠癌研究最充分。酪酸梭菌已在多项临床研究中展现“增效减毒”双重作用。

参考文献

[1] Bray F, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2024, 74(3):229-263. [2] Han B, et al. Cancer incidence and mortality in China, 2022. J Natl Cancer Cent, 2024, 4(1):47-53. [3] Cao W, et al. Comparative study of cancer profiles between 2020 and 2022 using global cancer statistics (GLOBOCAN). J Natl Cancer Cent, 2024, 4(2):128-134. [4] Böhm D, et al. The role of the gut microbiota in chemotherapy response, efficacy and toxicity: a systematic review. NPJ Precis Oncol, 2025, 9(1):265. [5] Bukowski K, Kciuk M, Kontek R. Mechanisms of Multidrug Resistance in Cancer Chemotherapy. Int J Mol Sci, 2020, 21(9). [6] Vodenkova S, et al. 5-fluorouracil and other fluoropyrimidines in colorectal cancer: Past, present and future. Pharmacol Ther, 2020, 206:107447. [7] Vasan N, Baselga J, Hyman DM. A view on drug resistance in cancer. Nature, 2019, 575(7782):299-309. [8] Huang L, et al. Study of prevalence and risk factors of chemotherapy-induced mucositis in gastrointestinal cancer using machine learning models. Front Oncol, 2023, 13:1138992. [9] Touchefeu Y, et al. Systematic review: the role of the gut microbiota in chemotherapy- or radiation-induced gastrointestinal mucositis. Aliment Pharmacol Ther, 2014, 40(5):409-21. [10] Akbarali HI, et al. Chemotherapy induced gastrointestinal toxicities. Adv Cancer Res, 2022, 155:131-166. [11] Gao W, et al. Butyrate-producing Eubacterium rectale inhibits gastric carcinogenesis and augments the efficacy of immunotherapy. J Transl Med, 2026, 24(1). [12] Yi Y, et al. Gut Microbiome Components Predict Response to Neoadjuvant Chemoradiotherapy in Patients with Locally Advanced Rectal Cancer: A Prospective, Longitudinal Study. Clin Cancer Res, 2021, 27(5):1329-1340. [13] Li N, et al. The Relationship Between Gut Microbiome Features and Chemotherapy Response in Gastrointestinal Cancer. Front Oncol, 2021, 11:781697. [14] Wu G, et al. A core microbiome signature as an indicator of health. Cell, 2024, 187(23):6550-6565.e11. [15] Saban Güler M, et al. Butyrate: A potential mediator of obesity and microbiome via different mechanisms of actions. Food Res Int, 2025, 199:115420. [16] Singhal K, et al. Modulation of NF-κB pathway in cancer therapy by sodium butyrate and Isoproterenol. Mol Biol Rep, 2025, 52(1):938. [17] Xu H, et al. Therapeutic potential of Clostridium butyricum anticancer effects in colorectal cancer. Gut Microbes, 2023, 15(1):2186114. [18] Dong Y, et al. Gut microbiota-derived short-chain fatty acids regulate gastrointestinal tumor immunity: a novel therapeutic strategy? Front Immunol, 2023, 14:1158200. [19] Cazzaniga M, et al. The Potential Role of Probiotics, Especially Butyrate Producers, in the Management of Gastrointestinal Mucositis Induced by Oncologic Chemo-Radiotherapy. Int J Mol Sci, 2024, 25(4). [20] Peng Y, et al. Microbial Metabolites in Colorectal Cancer: Basic and Clinical Implications. Metabolites, 2021, 11(3). [21] Al-Qadami GH, et al. Gut Microbiota-Derived Short-Chain Fatty Acids: Impact on Cancer Treatment Response and Toxicities. Microorganisms, 2022, 10(10). [22] He Y, et al. Gut microbial metabolites facilitate anticancer therapy efficacy by modulating cytotoxic CD8(+) T cell immunity. Cell Metab, 2021, 33(5):988-1000.e7. [23] Miao X, et al. Inhibition of indoleamine 2,3-dioxygenase 1 synergizes with oxaliplatin for efficient colorectal cancer therapy. Mol Ther Methods Clin Dev, 2021, 20:442-450. [24] Donohoe DR, et al. The microbiome and butyrate regulate energy metabolism and autophagy in the mammalian colon. Cell Metab, 2011, 13(5):517-26. [25] 江学良, 等. 产丁酸菌与肠道健康:从病理机制到肠病精准防治的研究进展. 生物谷, 2026-04-07. [26] Tian Y, et al. Effects of probiotics on chemotherapy in patients with lung cancer. Oncol Lett, 2019, 17(3):2836-2848. [27] Kapandji N, et al. Unravelling neutropenic enterocolitis: insights from gut microbiota, and intestinal barrier analyses. Exp Hematol Oncol, 2025, 14(1):74. [28] Kim N, Yang C. Sodium Butyrate Enhances 5-Fluorouracil Sensitivity Through Thymidylate Synthase Regulation and Cell-Cycle Modulation in Gastric Cancer. Mol Nutr Food Res, 2025, 69(19):e70152. [29] Li L, et al. Histone deacetylase inhibitor sodium butyrate suppresses DNA double strand break repair induced by etoposide more effectively in MCF-7 cells than in HEK293 cells. BMC Biochem, 2015, 16:2. [30] Yuille S, et al. Human gut bacteria as potent class I histone deacetylase inhibitors in vitro through production of butyric acid and valeric acid. PLoS One, 2018, 13(7):e0201073. [31] Gasaly N, Hermoso MA, Gotteland M. Butyrate and the Fine-Tuning of Colonic Homeostasis: Implication for Inflammatory Bowel Diseases. Int J Mol Sci, 2021, 22(6). [32] Li Y, et al. Combining Sodium Butyrate With Cisplatin Increases the Apoptosis of Gastric Cancer In Vivo and In Vitro via the Mitochondrial Apoptosis Pathway. Front Pharmacol, 2021, 12:708093. [33] Pant K, et al. Butyrate induces ROS-mediated apoptosis by modulating miR-22/SIRT-1 pathway in hepatic cancer cells. Redox Biol, 2017, 12:340-349. [34] Gnedina OO, Morshneva AV, Igotti MV. Sodium Butyrate Enhances the Cytotoxic Effect of Etoposide in HDACi-Sensitive and HDACi-Resistant Transformed Cells. Int J Mol Sci, 2023, 24(21). [35] Kumar M, et al. Bacterial metabolite butyrate in modulating sorafenib-targeted microRNAs to curtail its resistance in hepatocellular carcinoma. J Cancer Res Clin Oncol, 2023, 149(9):5823-5839. [36] Xiang Y, et al. Sodium butyrate enhances sorafenib-induced ferroptosis and immunogenic cell death by modulating IRF2-Oasl2-cGAS pathway in colorectal cancer. Mater Today Bio, 2025, 35:102498. [37] Shin H, Park JS. Fermenting T cell stemness for cancer immunity. Immunity, 2025, 58(11):2621-2623. [38] Bachem A, et al. Microbiota-derived butyrate promotes a FOXO1-induced stemness program and preserves CD8(+) T cell immunity against melanoma. Immunity, 2025, 58(11):2799-2813.e8. [39] Di Grazia A, et al. Rafoxanide Induces Immunogenic Death of Colorectal Cancer Cells. Cancers (Basel), 2020, 12(5). [40] Danne C, Sokol H. Butyrate, a new microbiota-dependent player in CD8+ T cells immunity and cancer therapy? Cell Rep Med, 2021, 2(7):100328. [41] Gou Y, et al. Gut microbiota derived butyrate enhances ferroptosis sensitivity in endometriosis through FFAR2/PPAR-γ/PINK1/Parkin mediated mitophagy. Free Radic Biol Med, 2025, 238:640-652. [42] Yang X, et al. Clostridium butyricum and its metabolite butyrate promote ferroptosis susceptibility in pancreatic ductal adenocarcinoma. Cell Oncol (Dordr), 2023, 46(6):1645-1658. [43] Bi R, et al. Butyrate enhances erastin-induced ferroptosis of lung cancer cells via modulating the ATF3/SLC7A11 pathway. Environ Toxicol, 2024, 39(2):529-538. [44] Bi R, et al. Butyrate attenuates the stemness of lung cancer cells through lysosome Fe(2+)- and SLC7A11-mediated ferroptosis. Heliyon, 2024, 10(7):e28093. [45] Zou H, Li H. Knockdown of long non-coding RNA LINC00152 increases cisplatin sensitivity in ovarian cancer cells. Exp Ther Med, 2019, 18(6):4510-4516. [46] Ben Toumia I, et al. A Methanol Extract of Scabiosa atropurpurea Enhances Doxorubicin Cytotoxicity against Resistant Colorectal Cancer Cells In Vitro. Molecules, 2020, 25(22). [47] Kim N, Yang C. Sodium Butyrate Inhibits the Expression of Thymidylate Synthase and Induces Cell Death in Colorectal Cancer Cells. Int J Mol Sci, 2024, 25(3). [48] Chen L, et al. Delivery of short chain fatty acid butyrate to overcome Fusobacterium nucleatum-induced chemoresistance. J Control Release, 2023, 363:43-56. [49] Ferreira TM, et al. Oral supplementation of butyrate reduces mucositis and intestinal permeability associated with 5-Fluorouracil administration. Lipids, 2012, 47(7):669-78. [50] Tian T, et al. The protective role of short-chain fatty acids acting as signal molecules in chemotherapy- or radiation-induced intestinal inflammation. Am J Cancer Res, 2020, 10(11):3508-3531. [51] Yan H, Ajuwon KM. Butyrate modifies intestinal barrier function in IPEC-J2 cells through a selective upregulation of tight junction proteins and activation of the Akt signaling pathway. PLoS One, 2017, 12(6):e0179586. [52] Zhao HB, et al. Effect of Clostridium butyricum and Butyrate on Intestinal Barrier Functions: Study of a Rat Model of Severe Acute Pancreatitis With Intra-Abdominal Hypertension. Front Physiol, 2020, 11:561061. [53] Dai X, et al. Maternal sucralose intake alters gut microbiota of offspring and exacerbates hepatic steatosis in adulthood. Gut Microbes, 2020, 11(4):1043-1063. [54] Sun Q, et al. Sodium Butyrate Alleviates Intestinal Inflammation in Mice with Necrotizing Enterocolitis. Mediators Inflamm, 2021, 2021:6259381. [55] Zhao X, et al. Combination of thalidomide and Clostridium butyricum relieves chemotherapy-induced nausea and vomiting via gut microbiota and vagus nerve activity modulation. Front Immunol, 2023, 14:1220165. [56] Cheatham SM, et al. Butyrate prevents chemotherapy-induced gastrointestinal toxicity and microbial dysbiosis. Sci Rep, 2025, 16(1):785. [57] Li G, et al. Desulfovibrio desulfuricans and its derived metabolites confer resistance to FOLFOX through METTL3. EBioMedicine, 2024, 102:105041. [58] Shuwen H, et al. Synergistic effect of sodium butyrate and oxaliplatin on colorectal cancer. Transl Oncol, 2023, 27:101598. [59] 王沁, 等. 酪酸梭菌活菌片对结直肠癌术后FOLFOX4方案化疗肠道菌群平衡、毒副反应及免疫炎症指标的影响. 世界华人消化杂志, 2021, 29(8):435-442. [60] 汪坤, 李龙, 王新建. 酪酸梭菌活菌片对直肠癌新辅助放化疗患者不良反应、炎性因子及营养状况的影响. 中国社区医师, 2024, 40(1):39-41. [61] Liu M, et al. Clostridium butyricum modulates gut microbiota and reduces colitis associated colon cancer in mice. Int Immunopharmacol, 2020, 88:106862. [62] Huang X, et al. Butyrate Alleviates Cytokine-Induced Barrier Dysfunction by Modifying Claudin-2 Levels. Biology (Basel), 2021, 10(3). [63] Cong J, et al. A Pilot Study: Favorable Effects of Clostridium butyricum on Intestinal Microbiota for Adjuvant Therapy of Lung Cancer. Cancers (Basel), 2022, 14(15). [64] Tomita Y, et al. Association of Clostridium butyricum Therapy Using the Live Bacterial Product CBM588 with the Survival of Patients with Lung Cancer Receiving Chemoimmunotherapy Combinations. Cancers (Basel), 2023, 16(1). [65] Liu G, et al. Effect of perioperative probiotic supplements on postoperative short-term outcomes in gastric cancer patients receiving neoadjuvant chemotherapy: A double-blind, randomized controlled trial. Nutrition, 2022, 96:111574. [66] 戚宇锋, 苏文, 蒋华. 胃癌患者肠道菌群失调与细胞因子表达异常的关联分析及临床意义. 肿瘤防治研究, 2026, 53(6):475-481. [67] Sono M, et al. Reduction of butyrate-producing bacteria in the gut microbiome of Japanese patients with pancreatic cancer. Pancreatology, 2024, 24(7):1031-1039. [68] Han ZY, et al. Probiotic Spore-Based Oral Drug Delivery System for Enhancing Pancreatic Cancer Chemotherapy by Gut-Pancreas-Axis-Guided Delivery. Nano Lett, 2022, 22(21):8608-8617. [69] 产丁酸菌对冷热肿瘤转化的机制研究进展. 丁香园, 2026-06-22. [70] 国家药品监督管理局. 境内生产药品——国药准字S20040088[EB/OL]. 2004. [71] 国家药品监督管理局. 境内生产药品——国药准字S20040084[EB/OL]. 2004.

品牌 Logo(全站页头页脚同步更换)

青岛东海药业有限公司

医用微生态制品开发国家地方联合工程研究中心

以创造健康为己任,专注微生态药品、保健食品与普通食品的创研、生产和销售,助力健康中国。

联系方式

  • 健康咨询:400-168-9885
  • 招商热线:0532-87199669
  • xzzx@qdeastsea.cn
  • 山东省青岛市黄岛区胶州湾西路 1377 号

官方渠道

温馨提示:药品请按说明书或在药师指导下购买和使用;保健食品不是药物,不能代替药物治疗疾病。

关注我们

公众号二维码公众号
公司微博二维码微博
公司小红书二维码小红书

扫码关注东海药业官方账号。

Copyright © 2003-2026 青岛东海药业有限公司 版权所有鲁ICP备16002916号常见问题管理后台